Download PDF
Dtsch Med Wochenschr 2015; 140(09): 684-686
DOI: 10.1055/s-0041-101663
Fachwissen
Standpunkt
© Georg Thieme Verlag KG Stuttgart · New York

Gentherapie in Deutschland: Von der ersten klinischen Studie bis heute

Gene therapy in Germany: from past to present
Young Kim
1   Centrum für Integrierte Onkologie Köln Bonn, Medizinische Klinik und Poliklinik III, Universitätsklinikum Bonn
,
Ingo G. H. Schmidt-Wolf
1   Centrum für Integrierte Onkologie Köln Bonn, Medizinische Klinik und Poliklinik III, Universitätsklinikum Bonn
› Author Affiliations
Further Information

Publication History

Publication Date:
29 April 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

1994 wurde in Deutschland die erste Klinische Studie zur Gentherapie durchgeführt. Seitdem gab es eine Vielzahl weiterer gentherapeutischer Studien, weltweit über 2000. Nach 20 Jahren soll hier ein kurzes Resümee gezogen werden.

Abstract

In 1994, the first clinical gene therapy trial was performed in Germany. Since then more than 2000 clinical gene therapy trials have been performed worldwide. After 20 years, a short résumé is drawn here.

Schlüsselwörter

Gentherapie - klinische Studien - Gentransfer - Vektoren

Key Words

gene therapy - clinical trials - gene transfer - vectors
 

  • Literaturverzeichnis

  • 1 Brill TH, Kübler HR, Pohla H et al. Therapeutic vaccination with an interleukin-2-interferon-gamma-secreting allogeneic tumor vaccine in patients with progressive castration-resistant prostate cancer: a phase I/II trial. Hum Gene Ther 2009; 20: 1641-1651
    CrossrefPubMedGoogle Scholar
  • 2 Hanahan D, Weinberg RA. The hallmarks of cancer. Cell  2000; 100: 57-70
    CrossrefPubMedGoogle Scholar
  • 3 Löhr M, Bago ZT, Bergmeister H et al. Cell therapy using microencapsulated 293 cells transfected with a gene construct expressing CYP2B1, an ifosfamide converting enzyme, instilled intra-arterially in patients with advanced-stage pancreatic carcinoma: a phase I/II study. J Mol Med 1999; 77: 393-398
    CrossrefPubMedGoogle Scholar
  • 4 Schuler M, Herrmann R, De Greve JL et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol 2001; 19: 1750-1758
    PubMedGoogle Scholar
  • 5 Ng SK. Generation of high-expressing cells by methotrexate amplification of destabilized dihydro­folate reductase selection marker. Methods Mol Biol 2012; 801: 161-172
    PubMedGoogle Scholar
  • 6 Shimoyamada H, Yazawa T, Sato H et al. Early growth response-1 induces and enhances vascular endothelial growth factor-A expression in lung cancer cells. Am J Pathol 2010; 177: 70-83
    PubMedGoogle Scholar
  • 7 Schwartz MA, Kolhatkar NS, Thouvenel C et al. CD4+ T cells and CD40 participate in selection and homeostasis of peripheral B cells. J Immunol 2014; 193: 3492-3502
    CrossrefPubMedGoogle Scholar
  • 8 Schmidt-Wolf IGH, Neubauer A, Finke S et al. Interleukin-7 gene therapy for patients with metastatic colon cancer, renal cell cancer, malignant melanoma or lymphoma. Human Gene Ther 1994; 5: 1161-1168
    CrossrefPubMedGoogle Scholar
  • 9 Wittig B, Märten A, Dorbic T et al. Therapeutic vaccination against metastatic carcinoma by auto­logous tumor cells transfected with interleukin-7, GM-CSF and immunostimulatory oligonucleotides: Preclinical results and outcome of a first clinical phase I/II trial. Human Gene Therapy 2001; 12: 267-278
    CrossrefPubMedGoogle Scholar
  • 10 Schmidt-Wolf IGH, Finke S, Trojaneck B et al. Phase I clinical study applying autologous immunologic effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Brit J Cancer 1999; 81: 1009-1016
    CrossrefPubMedGoogle Scholar
  • 11 Westphal M, Ylä-Herttuala S, Martin J et al. Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol 2013; 823-333
    PubMedGoogle Scholar
  • 12 Westermann J, Flörcken A, Willimsky G et al. Allogeneic gene-modified tumor cells (RCC-26 / IL-7 / CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study. Gene Ther 2011; 354-363
    PubMedGoogle Scholar
  • 13 Buchner A, Pohla H, Willimsky G et al. Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80 / IL-2 in patients with metastatic renal cell carcinoma. Hum Gene Ther 2010; 21: 285-297
    CrossrefPubMedGoogle Scholar
  • 14 Märten A, Renoth S, Heinicke T et al. Allogeneic dendritic cells fused with tumor cells: Preclinical results and outcome of a first clinical phase I/II trial in patients with renal cell carcinoma. Hum Gene Ther 2003; 4: 483-494
    PubMedGoogle Scholar
  • 15 Ledford H. Targeted gene editing enters clinic. Nature  2011; 471: 16
    CrossrefPubMedGoogle Scholar
  • 16 Kilian EG, Sadoni S, Vicol C et al. Myocardial trans­fection of hypoxia inducible factor-1alpha via an adenoviral vector during coronary artery bypass grafting. – A multicenter phase I and safety study. Circ J  2010; 74: 916-924
    PubMedGoogle Scholar
  • 17 von der Leyen HE, Mügge A, Hanefeld C et al. A prospective, single-blind, multicenter, dose escalation study of intracoronary iNOS lipoplex (CAR-MP583) gene therapy for the prevention of restenosis in patients with de novo or restenotic coronary artery lesion. Hum Gene Ther 2011; 951-958
    PubMedGoogle Scholar